Melanoma Vaccine Camp Lejeune NC

A vaccine for advanced melanoma has shown promise in a new study. Melanoma is the most serious type of skin cancer in Camp Lejeune. The five year-survival rates for local and metastatic melanoma are 65 percent and 16 percent, respectively. In 2009, an estimated 69,000 people in the United States will be diagnosed with melanoma and about 8,600 will die of the disease, according to the American Cancer Society.

Richard O'neal Lynch
(910) 451-5243
119 C Street
Camp Lejeune, NC
Specialty
Family Practice

Data Provided by:
Philip Adam ZurOwsky
(910) 450-4840
1100 Brewster Blvd
Camp Lejeune, NC
Specialty
Internal Medicine, Emergency Medicine

Data Provided by:
Ruth W Guyer
(910) 353-4991
217 Station St
Jacksonville, NC
Specialty
Family Practice

Data Provided by:
Eusebio Chiong Desuyo
(910) 455-9398
3652 Henderson Dr
Jacksonville, NC
Specialty
Internal Medicine, Pulmonary Disease, Critical Care (Intensivists)

Data Provided by:
John C Gudger
(910) 577-2240
317 Western Blvd
Jacksonville, NC
Specialty
General Practice, Emergency Medicine

Data Provided by:
Charles Edward McCannon, MD
(301) 295-3717
Camp Lejeune, NC
Specialties
Preventive Medicine, Aerospace Medicine, General Practice
Gender
Male
Education
Medical School: Uniformed Services Univ Of The Hlth Sci, Bethesda Md 20814
Graduation Year: 1994

Data Provided by:
Earlie T Johnson
(910) 346-1188
2580 Henderson Dr
Jacksonville, NC
Specialty
Internal Medicine

Data Provided by:
Ricky Allan Thomas
(910) 938-3200
2587 Henderson Dr
Jacksonville, NC
Specialty
Family Practice

Data Provided by:
Gregory Dean Streeter
(910) 353-0565
200 Doctor Dr
Jacksonville, NC
Specialty
Family Practice

Data Provided by:
Charles Edward Mc Cannon, MD
(301) 295-3717
Jacksonville, NC
Specialties
Preventive Medicine, Aerospace Medicine, General Practice
Gender
Male
Education
Medical School: Uniformed Services Univ Of The Hlth Sci, Bethesda Md 20814
Graduation Year: 1994

Data Provided by:
Data Provided by:

Melanoma Vaccine

Provided By:

SATURDAY, May 30 (HealthDay News) --A vaccine for advanced melanoma has shown promise in a new study.

Melanoma is the most serious type of skin cancer. The five year-survival rates for local and metastatic melanoma are 65 percent and 16 percent, respectively. In 2009, an estimated 69,000 people in the United States will be diagnosed with melanoma and about 8,600 will die of the disease, according to the American Cancer Society.

The study, a phase 3 clinical trial involving 185 people, found that using the peptide vaccine in combination with the immunotherapy drug Interleukin-2 improved response rates and progression-free survival, according to University of Texas M.D. Anderson Cancer Center researchers, who said it was the first phase 3 trial to show a clinical benefit in a vaccine for melanoma.

Response rate and progression-free survival were 22.1 percent and 2.9 months, respectively, in people given the vaccine, compared with 9.7 percent and 1.6 months for those who were not vaccinated. Median overall survival was 17.6 months for the vaccine group and 12.8 months for the others.

The study, which was to be presented Saturday at the annual meeting of the American Society of Clinical Oncology in Orlando, Fla., was funded in part by Novartis, which makes Interleukin-2.

"Obviously this is a disease, in its advanced setting, in need of better therapies for our patients," study co-author Dr. Patrick Hwu, a professor and chairman of M.D. Anderson's Department of Melanoma Medical Oncology, said in a news release from the center.

"While more follow-up is needed, this study serves as a proof-of-principle for vaccines' role in melanoma and in cancer therapy overall," Hwu said. "If we can use the body's own defense system to attack tumor cells, we provide a mechanism for ridding the body of cancer without destroying healthy tissue."

The vaccine, called gp100:209-217 (200M), works by stimulating T-cells, which control immune response.

"This vaccine activates the body's cytotoxic T-cells to recognize antigens on the surface of the tumor," Hwu said. "The T-cells then secrete enzymes that poke holes in the tumor cell's membrane, causing it to disintegrate."

More information

The Skin Cancer Foundation has more about melanoma.

SOURCE: University of Texas M.D. Anderson Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com